PROSTATE/KLK-L1 IS DIFFERENTIALLY EXPRESSED IN NORMAL/BENIGN VERSUS MALIGNANT OVARIAN TISSUES

Obiezu, C.V. 1,2 Scorilas, A. 1,2 Kim, H. 1,2 and Diamandis, E.P. 1,2 Dept. of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5; Dept. of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada M5G 1L5

Objectives: Prostate/KLK-L1 is a newly discovered member of the human kallikrein-like gene family. It has been shown that it is upregulated by androgens in the LNCaP prostatic carcinoma cell line, and by both androgens and progestins in the BT-474 breast cancer cell line. Based on its apparent association with hormonally regulated tissues, we have undertaken to screen normal, benign and malignant ovarian tissues for possible differential KLK-L1 expression.

Methods: Tissues were pulverized and total RNA was extracted using the Trizol® method. RNA was quantified by spectrophotometry, and was reverse-transcribed into cDNA. Using primers specific for KLK-L1, we amplified this gene by PCR. Identity of the PCR product was verified by sequencing.

Results: Based on 10 normal, 10 benign and 20 cancerous tissues, KLK-L1 is highly expressed in 50% of cancerous tissues but only in 15% of normal or benign tissues. 60% of normal/benign tissues do not express this gene whereas this is the case only in 20% of tumour tissues. These differences were statistically significant using Chi Square test ($p = 0.02$). There is no significant difference of KLK-L1 expression between normal and benign tissues.

Conclusions: Our finding may have applicability for the diagnosis and management of ovarian carcinoma. Currently we are developing immunoassays to examine KLK-L1 levels in tissues of ovarian cancer patients.